-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Three Medical Device Products of Hanlin Biotechnology under Shijiazhuang Sihua Pharmaceutical Group Have Been Approved
Category:
发布时间：2025-02-10
【概要描述】
On February 8, three new medical device products—medical sodium hyaluronate wound gel dressings, medical recombinant humanized collagen wound gel dressings, and medical sodium hyaluronate liquid wound dressings—developed and manufactured by Hebei Hanlin Biotechnology Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, were approved. This follows the January 22 approval of the in vitro diagnostic reagent myoglobin (MYO) test kit (fluorescent immuno-chromatographic assay), bringing Hanlin Biotechnology’s total number of newly approved product registrations this year to four.
On February 8, three new medical device products—medical sodium hyaluronate wound gel dressings, medical recombinant humanized collagen wound gel dressings, and medical sodium hyaluronate liquid wound dressings—developed and manufactured by Hebei Hanlin Biotechnology Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, were approved. This follows the January 22 approval of the in vitro diagnostic reagent myoglobin (MYO) test kit (fluorescent immuno-chromatographic assay), bringing Hanlin Biotechnology’s total number of newly approved product registrations this year to four.
Currently, Hanlin Biotechnology has cumulatively obtained approval for 12 medical devices and 3 in vitro diagnostic reagents, with an increasingly diversified product portfolio and continuous structural optimization.
According to available information, the three medical devices recently approved for Hanlin Biotechnology are all aesthetic-medicine products. They primarily function by forming a protective layer on the wound surface, thereby providing a physical barrier and supporting skin care.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091